Rigosertib

Drug Profile

Rigosertib

Alternative Names: Estybon; Novonex; ON-01910; ON-01910-sodium; ON-01910.Na; Rigosertib sodium; SyB C-1101; SyB L-1101; SyB-1101

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Onconova Therapeutics
  • Developer Onconova Therapeutics; SymBio Pharmaceuticals
  • Class Amino acids; Antineoplastics; Small molecules; Sulfones
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Myelodysplastic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia; Solid tumours
  • Phase I Head and neck cancer
  • No development reported Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Ovarian cancer; Pancreatic cancer
  • Discontinued Squamous cell cancer

Most Recent Events

  • 26 Sep 2016 Onconova Therapeutics plans a phase III trial for Myelodysplastic syndromes (First-line therapy, Combination therapy) in USA (PO)
  • 19 Jul 2016 SymBio announces intention to submit NDA to the Japanese Ministry of Health, Labour and Welfare
  • 19 Jul 2016 Phase-III clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in Japan (IV) (NCT02562443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top